Latest news with #AliGhamrawy
Zawya
6 days ago
- Business
- Zawya
Egypt's pharmaceutical market hits $6.21bln in 2024, marking 43% growth
Egypt's pharmaceutical market recorded EGP 309bn in sales in 2024, up from EGP 216bn in 2023—reflecting a 43% year-on-year increase, according to Ali Ghamrawy, Chairperson of the Egyptian Drug Authority (EDA). The announcement came during the EDA's 15th Board of Directors meeting, attended by Deputy Prime Minister for Human Development and Minister of Health and Population Khaled Abdel Ghaffar, Deputy Prime Minister for Industrial Development and Minister of Industry and Transport Kamel El-Wazir, Minister of Investment and Foreign Trade Hassan Mohamed El-Khatib, and Presidential Health Advisor Mohamed Awad Tag El-Din, alongside other senior officials. The meeting reviewed several strategic updates, including the latest activities of the Permanent Committee of the Egyptian Pharmacopeia and progress in digital transformation across the Authority. These digital initiatives aim to enhance service delivery efficiency and strengthen the institutional work environment. A key highlight of the meeting was the EDA's continued success in gaining international accreditation. In December 2024, the World Health Organization (WHO) awarded the Authority Maturity Level 3 status in the field of medicines—an achievement that follows its earlier Maturity Level 3 accreditation for vaccines in March 2022. EDA laboratories have also been accredited by both the WHO and the European Union, a milestone that positions them as globally recognized reference labs. The Authority's growing international presence was further underscored by its contributions to regulatory capacity-building programs across the Arab and African regions. With WHO Maturity Level 3 recognition in both medicine and vaccine regulation, the EDA has assumed a leading role in supporting regulatory system development throughout Africa. The African Union Development Agency – NEPAD (AUDA-NEPAD) has selected EDA's Continuing Professional Development Center as a Regional Centre of Regulatory Excellence (RCORE). Under this designation, the Authority has conducted 12 international training programs for countries including Libya, Yemen, Ghana, and Algeria. Additionally, the meeting showcased progress in EDA's internship programs, including the pilot launch of a new Learning Management System (LMS) platform aimed at enhancing professional training and knowledge transfer. © 2024 Daily News Egypt. Provided by SyndiGate Media Inc. (
Daily News Egypt
7 days ago
- Business
- Daily News Egypt
Egypt's pharmaceutical market hits EGP 309bn in 2024, marking 43% growth
Egypt's pharmaceutical market recorded EGP 309bn in sales in 2024, up from EGP 216bn in 2023—reflecting a 43% year-on-year increase, according to Ali Ghamrawy, Chairperson of the Egyptian Drug Authority (EDA). The announcement came during the EDA's 15th Board of Directors meeting, attended by Deputy Prime Minister for Human Development and Minister of Health and Population Khaled Abdel Ghaffar, Deputy Prime Minister for Industrial Development and Minister of Industry and Transport Kamel El-Wazir, Minister of Investment and Foreign Trade Hassan Mohamed El-Khatib, and Presidential Health Advisor Mohamed Awad Tag El-Din, alongside other senior officials. The meeting reviewed several strategic updates, including the latest activities of the Permanent Committee of the Egyptian Pharmacopeia and progress in digital transformation across the Authority. These digital initiatives aim to enhance service delivery efficiency and strengthen the institutional work environment. A key highlight of the meeting was the EDA's continued success in gaining international accreditation. In December 2024, the World Health Organization (WHO) awarded the Authority Maturity Level 3 status in the field of medicines—an achievement that follows its earlier Maturity Level 3 accreditation for vaccines in March 2022. EDA laboratories have also been accredited by both the WHO and the European Union, a milestone that positions them as globally recognized reference labs. The Authority's growing international presence was further underscored by its contributions to regulatory capacity-building programs across the Arab and African regions. With WHO Maturity Level 3 recognition in both medicine and vaccine regulation, the EDA has assumed a leading role in supporting regulatory system development throughout Africa. The African Union Development Agency – NEPAD (AUDA-NEPAD) has selected EDA's Continuing Professional Development Center as a Regional Centre of Regulatory Excellence (RCORE). Under this designation, the Authority has conducted 12 international training programs for countries including Libya, Yemen, Ghana, and Algeria. Additionally, the meeting showcased progress in EDA's internship programs, including the pilot launch of a new Learning Management System (LMS) platform aimed at enhancing professional training and knowledge transfer.
Zawya
24-02-2025
- Business
- Zawya
Egyptian Drug Authority, Sandoz discuss oncology drug localisation
Egypt - The Chairperson of the Egyptian Drug Authority (EDA), Ali Ghamrawy, has met with a high-level delegation from Sandoz, a global pharmaceutical company, to discuss strengthening cooperation and localising the production of oncology drugs in Egypt. The Sandoz delegation was headed by Cenkiz Zaim, Head of META (Middle East, Turkey, and Africa) at Sandoz, and included Sameh El-Bagoury, Head of Sandoz Egypt, and Ola Sadek, Head of Regulatory Affairs and Scientific Office Manager. Amani Gouda, Assistant to the Chairperson of the EDA for the Office Affairs, also attended the meeting. The meeting served as a platform to announce Sandoz Egypt's new regional head and was held within the framework of strengthening the strategic cooperation between the EDA and Sandoz in the pharmaceutical sector. Discussions focused on expanding Sandoz's presence in the Egyptian market, promoting joint collaboration, and exchanging views on strategic points such as localising the production of oncology drugs and the future of biosimilars. Opportunities and challenges in the sector were also reviewed. The general vision for cooperation between the EDA and Sandoz Egypt was presented, with the aim of supporting innovation and enhancing patient access to advanced treatments, contributing to the development of the Egyptian health system and achieving drug security. Ghamrawy welcomed the Sandoz delegation and praised the strong relationship between the two parties. He highlighted the EDA's commitment to deepening relations with Sandoz Egypt and fostering an environment for increased investment in Egypt, particularly in localising the production of essential and innovative pharmaceuticals, specifically oncology drugs. He explained that the EDA had seen significant progress in its digital infrastructure and that regulatory developments were enhancing investment opportunities. The EDA, he said, is providing all necessary facilities to support the work of industry partners within the Egyptian pharmaceutical system, in line with the Egyptian government's objectives of achieving localisation and exporting abroad. This cooperation is part of Sandoz's commitment to supporting the health sector in Egypt and contributing to strengthening local manufacturing capabilities, in line with the Egyptian government's strategy towards achieving self-sufficiency in vital and essential medicines.
